BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30369356)

  • 1. [Value of multiparameter flow cytometry in the diagnosis and prognostic evaluation of childhood myelodysplastic syndrome].
    Liu C; An WB; Zhang JL; Zhang RR; Sun CC; Chang LX; Liu TF; Zou Y; Wang HJ; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Oct; 20(10):819-824. PubMed ID: 30369356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
    Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
    Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Multicolor Flow Cytometry Scoring System for the Diagnosis and Prognostic Stratification of Myelodysplastic Syndromes.
    Lai B; Chen Y; Li M; Ye G; Luo H; Zhong Y; Guo X
    Clin Lab; 2022 Sep; 68(9):. PubMed ID: 36125138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.
    Wells DA; Benesch M; Loken MR; Vallejo C; Myerson D; Leisenring WM; Deeg HJ
    Blood; 2003 Jul; 102(1):394-403. PubMed ID: 12649150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.
    Scott BL; Wells DA; Loken MR; Myerson D; Leisenring WM; Deeg HJ
    Blood; 2008 Oct; 112(7):2681-6. PubMed ID: 18606877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
    Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
    Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
    Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Leukemia; 2016 Mar; 30(3):658-65. PubMed ID: 26503643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Abnormality of immunophenotyping in patients with myelodysplastic syndrome].
    Xu J; Guo YX; Zhao H; Hui WH; Wan SG; Sun XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):894-7. PubMed ID: 19698224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome.
    Chung JW; Park CJ; Cha CH; Cho YU; Jang S; Chi HS; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
    Ann Clin Lab Sci; 2012; 42(3):271-80. PubMed ID: 22964615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research advances in value of flow cytometric immunophenotyping in diagnosis and prognostic evaluation of myelodysplastic syndrome].
    Lu D; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):785-90. PubMed ID: 23815941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De-Novo, Particularly Low-Grade Myelodysplastic Syndromes.
    Gardikas N; Vikentiou M; Konsta E; Kontos CK; Papageorgiou SG; Spathis A; Bazani E; Bouchla A; Kapsimali V; Psarra K; Foukas P; Dimitriadis G; Pappa V
    Cytometry B Clin Cytom; 2019 Jan; 96(1):73-82. PubMed ID: 30334347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes.
    Kárai B; Bedekovics J; Miltényi Z; Gergely L; Szerafin L; Ujfalusi A; Kappelmayer J; Hevessy Z
    Int J Lab Hematol; 2017 Dec; 39(6):577-584. PubMed ID: 28625017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
    van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
    Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic significance of immunophenotyping of bone marrow cells in myelodysplastic syndrome without an increase of marrow blasts].
    Xu J; Zhang W; Liu Y; Wan SG; Sun XJ; Zhao H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1477-81. PubMed ID: 20030930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.
    Kern W; Haferlach C; Schnittger S; Haferlach T
    Cancer; 2010 Oct; 116(19):4549-63. PubMed ID: 20572043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact.
    Oelschlaegel U; Oelschlaeger L; von Bonin M; Kramer M; Sockel K; Mohr B; Wagenfuehr L; Kroschinsky F; Bornhaeuser M; Platzbecker U
    Cytometry B Clin Cytom; 2023 Mar; 104(2):141-150. PubMed ID: 34390327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.